What is the recommended management for nephrolithiasis?

Management of Nephrolithiasis

All patients with nephrolithiasis should immediately increase fluid intake to achieve at least 2 liters of urine output daily, and if stones recur despite adequate hydration, initiate pharmacologic monotherapy with either a thiazide diuretic, potassium citrate, or allopurinol based on stone composition and metabolic profile. 1

Initial Approach: Hydration First

• Increase fluid intake throughout the day to produce at least 2 liters of urine per 24 hours, which reduces stone recurrence by approximately 55% (relative risk 0.45) 1, 2
• Distribute fluid intake evenly across day and night to prevent nocturnal urinary supersaturation 3
• Water is the preferred beverage; avoid soft drinks acidified with phosphoric acid (colas), as these increase stone risk 1
• This intervention alone prevents recurrence in many patients and has no adverse effects 1

Dietary Modifications (Concurrent with Hydration)

• Maintain normal dietary calcium intake of 1,000-1,200 mg daily—never restrict calcium, as restriction paradoxically increases urinary oxalate and stone formation risk 2, 4
• Limit sodium intake to ≤2,300 mg daily to reduce urinary calcium excretion 2, 4
• Reduce non-dairy animal protein to 5-7 servings weekly, as animal protein generates sulfuric acid that increases urinary calcium and reduces citrate 2, 4
• Limit high-oxalate foods (nuts, chocolate, tea, spinach, wheat bran) particularly in patients with hyperoxaluria 2
• Consume dietary calcium with meals to bind intestinal oxalate and reduce absorption 5

Pharmacologic Therapy: When Hydration Fails

Initiate monotherapy when increased fluid intake fails to prevent stone recurrence—combination therapy offers no additional benefit and increases adverse effects. 1

Stone-Specific Pharmacologic Selection:

For Calcium Oxalate/Phosphate Stones (80% of cases):

• Thiazide diuretics for hypercalciuria: Hydrochlorothiazide 50 mg daily, chlorthalidone 25-50 mg daily, or indapamide 2.5 mg daily reduces stone recurrence from 48.5% to 24.9% 1, 2
• Potassium citrate for hypocitraturia or low urinary pH: Target urinary citrate >320 mg/day, reduces stone recurrence from 52.3% to 11.1% 1, 2
• Allopurinol 200-300 mg daily for hyperuricosuria with normal urinary calcium: Reduces stone recurrence from 55.4% to 33.3% 1, 2

For Uric Acid Stones:

• Potassium citrate is first-line therapy to alkalinize urine to pH 6.0, as most patients have low urinary pH rather than hyperuricosuria 1, 4
• Do not use allopurinol as first-line therapy for uric acid stones—alkalinization addresses the primary defect 1
• Oral chemolysis with alkalinization (citrate or sodium bicarbonate to pH 7.0-7.2) can dissolve existing uric acid stones 4

For Cystine Stones:

• First-line: Increased fluid intake, sodium/protein restriction, and potassium citrate to achieve urine pH 7.0 1, 4
• Second-line: Cystine-binding thiol drugs (tiopronin preferred over d-penicillamine) for patients unresponsive to first-line therapy or with large recurrent stone burdens 1

For Struvite Stones:

• Urease inhibitor (acetohydroxamic acid) may be beneficial but has extensive side effect profile limiting use 1
• Monitor for reinfection 1

Metabolic Evaluation and Monitoring

• Obtain 24-hour urine collection measuring volume, pH, calcium, oxalate, uric acid, citrate, sodium, potassium, and creatinine 1, 2, 4
• Perform initial follow-up collection within 6 months of treatment initiation to assess response 1, 4
• Continue annual 24-hour urine collections to assess adherence and metabolic response 1, 4
• Obtain stone analysis for all first-time stone formers and repeat analysis in non-responders, as composition may change 1, 4

Monitoring for Adverse Effects

Obtain periodic blood testing in patients on pharmacologic therapy: 1, 4

• Thiazides: Monitor for hypokalemia and glucose intolerance 1, 4
• Allopurinol and tiopronin: Monitor liver enzymes 1, 4
• Acetohydroxamic acid and tiopronin: Monitor for anemia and hematologic abnormalities 1, 4
• Potassium citrate: Monitor for hyperkalemia 1, 4

Critical Pitfalls to Avoid

• Never restrict dietary calcium—this increases urinary oxalate and stone risk 2, 5
• Never use sodium-based alkali (sodium citrate/bicarbonate) instead of potassium citrate, as sodium load increases urinary calcium excretion 5
• Never use combination pharmacologic therapy as first-line—monotherapy is equally effective with fewer side effects 1, 2
• Avoid calcium supplements unless specifically indicated; prefer dietary calcium consumed with meals 2, 5
• Avoid vitamin C supplements >1,000 mg/day, as vitamin C metabolizes to oxalate 2, 5
• Do not use allopurinol as first-line for uric acid stones when urinary pH is the primary abnormality 1

Evidence Quality Considerations

The American College of Physicians guidelines 1 and American Urological Association guidelines 1 represent the highest quality evidence available from 2014. Both emphasize that while evidence for fluid intake is low-quality, the intervention is safe and effective. Pharmacologic evidence is moderate-quality, with thiazides, citrates, and allopurinol all demonstrating efficacy for calcium stones, though no head-to-head trials exist comparing these agents directly 1. The choice among pharmacologic agents should be guided by metabolic abnormalities when available, though randomized trial evidence supporting biochemistry-tailored treatment over empirical treatment remains limited 1, 4.